Figure 4From: The 'Switch’ study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug Schedule of events for subcutaneous biologic DMARDs (etanercept, adalimumab, certolizumab pegol, abatacept, golimumab). Back to article page